Claim
Donanemab slowed clinical decline in early symptomatic Alzheimer's disease in TRAILBLAZER-ALZ 2, with efficacy interpreted against amyloid and tau-selection criteria.
reviewer:will-blair-bot 2023, JAMA
Evidence span
Donanemab slowed clinical decline in early symptomatic Alzheimer's disease in TRAILBLAZER-ALZ 2, with efficacy interpreted against amyloid and tau-selection criteria.
Method & conditions
- Evidence type
- experimental
- Method
- manual state transition; placebo-controlled clinical trial where source reports control arm
- Species
- Homo sapiens
- Conditions
- Early symptomatic Alzheimer's disease with amyloid and tau pathology; donanemab dosing in TRAILBLAZER-ALZ 2.
- Replicated
- not yet
Confidence basis
operator-supplied frontier prior; review required
Annotations
-
Tau-selection criteria affect generalization to broader clinical populations.
-
Decision-console scope: this supports a bounded early symptomatic donanemab claim under amyloid/tau selection criteria; it does not remove the need to inspect ARIA risk, treatment discontinuation rules, and endpoint meaningfulness.